Fig 1.
Activating 5-HT2A but not 5-HT2B and 5-HT2C receptors suppresses S-IRA in DBA/1 mice.
A) Systemic administration of the 5-HT2A receptor agonist TCB-2 significantly reduced the incidence of S-IRA at 10 mg/kg compared with the vehicle control (dose zero). But, TCB-2 at 5 mg/kg or 1 mg/kg was ineffective in alleviating S-IRA. B, C) Injection of the 5-HT2B receptor agonist BW723C86 at 2–10 mg/kg or 5-HT2C receptor agonist MK-212 at 5–20 mg/kg exerted no effect on S-IRA compared with the corresponding vehicle control, respectively. ** p < 0.01: Significantly different from the vehicle control (dose zero) (Fisher’s exact test).
Fig 2.
Stimulating the function of 5-HT1A, 5-HT6 and 5-HT7 receptors engenders no effect on S-IRA in DBA/1 mice.
A, B, C) Systemic injection of the 5-HT1A receptor agonist 8-OH-DPAT at 1–10 mg/kg, 5-HT6 receptor agonist WAY-208466 at 5–30 mg/kg and 5-HT7 receptor agonist LP-211 at 0.25–1 mg/kg did not significantly alter the incidence of S-IRA compared with the corresponding vehicle control (dose zero) in DBA/1 mice, respectively. (Fisher’s exact test).